Resultados de la búsqueda 81-90 of 14465 for Hypercalcaemia

  1. Enfermedad de las arterias coronarias.

    Publicaciones · Ferri FF. Coronary artery disease. · Coronary heart disease. National Heart, Lung, and Blood Institute. · Usatine RP, et al., eds. · Wilson PWF.

  2. Hematología - Ensayos clínicos - Mayo Clinic

    The purpose of this research is to see if MR-guided cryoablation can effectively treat prostate tumor recurrences. Fertility Outcomes in Lymphoma Patients.

  3. Hematología - Ensayos clínicos - Mayo Clinic

    All study subjects will receive acalabrutinib, durvalumab, and venetoclax. Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small ...

  4. Hematología - Ensayos clínicos - Mayo Clinic

    This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...

  5. Hematología - Ensayos clínicos - Mayo Clinic

    Lymphoma is a diversified disease with outcomes differing upon the types and subtypes of lymphoma as well as treatment modalities used. Fertility outcomes in ...

  6. Hematología - Ensayos clínicos - Mayo Clinic

    This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...

  7. Hematología - Ensayos clínicos - Mayo Clinic

    This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...

  8. Hematología - Ensayos clínicos - Mayo Clinic

    All study subjects will receive acalabrutinib, durvalumab, and venetoclax. Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small ...

  9. Hematología - Ensayos clínicos - Mayo Clinic

    This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...

  10. Hematología - Ensayos clínicos - Mayo Clinic

    All study subjects will receive acalabrutinib, durvalumab, and venetoclax. Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small ...